Biglycan can stimulate the growth of mesenchymal-derived tumor cells: such mechanisms have been investigated, and biglycan was found to modulate the insulin-like growth factor receptor I (IGF-IR) and Wnt/β-catenin signaling cascade, thereby promoting osteosarcoma cell proliferation [234]. Here, IGF1R is linked to osteosarcoma.